XML 36 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Convertible Preferred Stock, Redeemable Common Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Convertible Preferred Stock
Redeemable Common Stock
Beginning balance, convertible preferred stock (in share) at Dec. 31, 2016           22,061,973 107,371
Beginning balance, convertible preferred stock at Dec. 31, 2016           $ 34,307 $ 734
Increase (Decrease) in Temporary Equity [Roll Forward]              
Repurchase of Series Seed convertible preferred stock, net of issuance costs of $11 $ 0            
Issuance cost of convertible preferred stock, net of issuance cost (in shares)           15,956,995  
Issuance costs of convertible preferred stock, net of issuance costs 0         $ 26,596  
Conversion of redeemable common stock into common stock 0            
Ending balance, convertible preferred stock (in shares) at Dec. 31, 2017           38,018,968 107,371
Ending balance, convertible preferred stock at Dec. 31, 2017           $ 60,903 $ 734
Beginning balance (in shares) at Dec. 31, 2016   345,856          
Beginning balance at Dec. 31, 2016 (23,052) $ 0 $ 884 $ 0 $ (23,936)    
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options (in shares)   4,751          
Exercise of stock options 9   9        
Stock-based compensation expense 492   492        
Net loss (21,994)       (21,994)    
Ending balance (in shares) at Dec. 31, 2017   350,607          
Ending balance at Dec. 31, 2017 (44,545) $ 0 1,385 0 (45,930)    
Increase (Decrease) in Temporary Equity [Roll Forward]              
Repurchase of Series Seed convertible preferred stock, net of issuance cost of $11,000 (in shares)           (598,975)  
Repurchase of Series Seed convertible preferred stock, net of issuance costs of $11 (22)       (22) $ (517)  
Issuance cost of convertible preferred stock, net of issuance cost (in shares)           2,659,574  
Issuance costs of convertible preferred stock, net of issuance costs 0         $ 4,289  
Conversion of redeemable common stock into common stock $ 0            
Ending balance, convertible preferred stock (in shares) at Dec. 31, 2018 40,079,567         40,079,567 107,371
Ending balance, convertible preferred stock at Dec. 31, 2018 $ 64,675         $ 64,675 $ 734
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options (in shares)   1,045          
Exercise of stock options 7   7        
Stock-based compensation expense 759   759        
Net loss (33,285)       (33,285)    
Ending balance (in shares) at Dec. 31, 2018   351,652          
Ending balance at Dec. 31, 2018 (77,086) $ 0 2,151 0 (79,237)    
Increase (Decrease) in Temporary Equity [Roll Forward]              
Repurchase of Series Seed convertible preferred stock, net of issuance costs of $11 0            
Conversion of redeemable common stock into common stock (in shares)   107,364         (107,371)
Conversion of redeemable common stock into common stock 734   734       $ (734)
Conversion of convertible preferred shares into common stock (in shares)   3,808,430       (40,079,567)  
Conversion of convertible preferred shares into common stock 64,675 $ 4 64,671     $ (64,675)  
Ending balance, convertible preferred stock (in shares) at Dec. 31, 2019           0 0
Ending balance, convertible preferred stock at Dec. 31, 2019           $ 0 $ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exchange of common stock in connection with Merger (in shares)   2,440,582          
Exchange of common stock in connection with Merger 45,541 $ 2 45,539        
Fair value of replacement equity awards 817   817        
Reclassification of warrant liability to permanent equity 5,235   5,235        
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.5 million (in shares)   9,336,667          
Issuance of common stock and prefunded warrants for the purchase of common stock, net of issuance costs of $11.4 million $ 139,388 $ 9 139,379        
Exercise of stock options (in shares) 51,617 50,321          
Exercise of stock options $ 345 $ 1 344        
Exercise of warrants (in shares)   33,846          
Exercise of warrants 447   447        
Stock-based compensation expense 2,050   2,050        
Foreign currency translation adjustment (119)     (119)      
Net loss (52,807)       (52,807)    
Ending balance (in shares) at Dec. 31, 2019   16,128,862          
Ending balance at Dec. 31, 2019 $ 129,220 $ 16 $ 261,367 $ (119) $ (132,044)